Payment overview · 2025
General Payments
$981.17
44 reported records · 15 companies
Healthcare provider profile · identity verified
Dylan Keith Barnett, MD
Allopathic & Osteopathic Physicians|Family Medicine · PARAGOULD, AR · NPI 1073075735
Verified facts
What the public records show
CMS Open Payments records show Dylan Keith Barnett, MD received $981.17 in general payments during 2025 across 44 reported records.
Novo Nordisk Inc accounted for 20.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Paxlovid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $201.10 | 20.5% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $201.03 | 20.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $143.45 | 14.6% | 12 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $101.92 | 10.4% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $83.14 | 8.5% | 3 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $54.91 | 5.6% | 2 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $34.89 | 3.6% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $33.06 | 3.4% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $24.37 | 2.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.00 | 2.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$19.93 | 2.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.15 | 1.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.41 | 1.7% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.12 | 1.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.69 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $981.17 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $201.03 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $187.33 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $187.33 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $185.06 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $138.53 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $88.93 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $76.01 | 7 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $54.91 | 2 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $54.91 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $48.67 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $48.55 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $42.61 | 4 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $34.89 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $33.06 | 2 | 2025 |
Source payment records
|
|||||
| FABRAZYME Normalized: fabrazyme |
Biological | GENZYME CORPORATION | $24.37 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $19.93 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.41 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 80 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 124 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 151 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 12 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 85 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
80 | 26 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
85 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
124 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
73 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
151 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
81 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 305 | 105 |
| Gabapentin | Gabapentin | 297 | 73 |
| Amlodipine Besylate | Amlodipine Besylate | 291 | 77 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 275 | 77 |
| Losartan Potassium | Losartan Potassium | 266 | 91 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 219 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 217 | 59 |
| Alprazolam | Alprazolam | 215 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 210 | 68 |
| Lisinopril | Lisinopril | 189 | 64 |
| Omeprazole | Omeprazole | 186 | 67 |
| Furosemide | Furosemide | 170 | 51 |
| Potassium Chloride | Potassium Chloride | 169 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 165 | 49 |
| Trazodone Hcl | Trazodone Hcl | 158 | 44 |
| Ozempic | Semaglutide | 151 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 145 | 55 |
| Clopidogrel | Clopidogrel Bisulfate | 142 | 38 |
| Metformin Hcl | Metformin Hcl | 136 | 51 |
| Buspirone Hcl | Buspirone Hcl | 134 | 34 |
| Metformin Hcl Er | Metformin Hcl | 131 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 126 | 35 |
| Jardiance | Empagliflozin | 124 | 31 |
| Quetiapine Fumarate | Quetiapine Fumarate | 124 | 22 |
| Meloxicam | Meloxicam | 121 | 42 |
| Pregabalin | Pregabalin | 120 | 38 |
| Prednisone | Prednisone | 115 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 113 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 97 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 96 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 94 | 28 |
| Ondansetron Odt | Ondansetron | 93 | 50 |
| Ropinirole Hcl | Ropinirole Hcl | 89 | 22 |
| Montelukast Sodium | Montelukast Sodium | 88 | 29 |
| Diclofenac Sodium | Diclofenac Sodium | 86 | 44 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 85 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 85 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 83 | 29 |
| Tramadol Hcl | Tramadol Hcl | 83 | 26 |
| Eliquis | Apixaban | 81 | 20 |
| Farxiga | Dapagliflozin Propanediol | 80 | 26 |
| Diazepam | Diazepam | 79 | 21 |
| Carvedilol | Carvedilol | 78 | 29 |
| Clonazepam | Clonazepam | 78 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 77 | 26 |
| Mounjaro | Tirzepatide | 73 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 70 | 21 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 69 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 67 | 22 |
| Donepezil Hcl | Donepezil Hcl | 66 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 63 | 17 |
| Sucralfate | Sucralfate | 61 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 56 | 14 |
| Promethazine Hcl | Promethazine Hcl | 54 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 52 | 20 |
| Celecoxib | Celecoxib | 51 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 51 | 12 |
| Spironolactone | Spironolactone | 51 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 44 |
| Famotidine | Famotidine | 50 | 17 |
| Mirtazapine | Mirtazapine | 49 | 21 |
| Sertraline Hcl | Sertraline Hcl | 49 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 48 | 13 |
| Methocarbamol | Methocarbamol | 46 | 28 |
| Topiramate | Topiramate | 44 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 43 | 13 |
| Lorazepam | Lorazepam | 41 | suppressed |
| Atenolol | Atenolol | 39 | 11 |
| Ezetimibe | Ezetimibe | 39 | 20 |
| Alendronate Sodium | Alendronate Sodium | 37 | 13 |
| Simvastatin | Simvastatin | 36 | 18 |
| Ibuprofen | Ibuprofen | 35 | 15 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 35 | suppressed |
| Linzess | Linaclotide | 35 | suppressed |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 32 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | 11 |
| Glipizide | Glipizide | 32 | suppressed |
| Allopurinol | Allopurinol | 31 | suppressed |
| Fluconazole | Fluconazole | 29 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Primidone | Primidone | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | 13 |
| Azithromycin | Azithromycin | 27 | 25 |
| Finasteride | Finasteride | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 21 |
| Terbinafine Hcl | Terbinafine Hcl | 27 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 21 |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 15 |
| Dilt-Xr | Diltiazem Hcl | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Sotalol | Sotalol Hcl | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | 12 |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Minoxidil | Minoxidil | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 17 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 15 |
| Nabumetone | Nabumetone | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Movantik | Naloxegol Oxalate | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 14 |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Roflumilast | Roflumilast | 14 | suppressed |
| Zaleplon | Zaleplon | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Humulin R U-500 | Insulin Regular, Human | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 13 | suppressed |
| Methadone Hcl | Methadone Hcl | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 11 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $981.17 · 44 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, Dyanavel XR, FABRAZYME, FARXIGA, Fluad, Flucelvax, INCEPTIV, JARDIANCE, Kerendia, Ozempic, PAXLOVID, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZENPEP | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error